Q-omics provides the consensus-scored RPL12P23 profile across patient tissues and cancer cell-line models. RPL12P23 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RPL12P23 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RPL12P23 RNA expression shows 6,133 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight DLBC, BRCA, and GBM as cancer lineages where RPL12P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P23 survival associations across molecular data types. RPL12P23 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P23 RNA expression–survival associations across cancer types. High RPL12P23 expression shows unfavorable associations in DLBC, SKCM, STAD, LUSC and KIRP, but favorable associations in UCEC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RPL12P23 RNA expression.
This table summarizes RPL12P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P23 shows lower tumor expression in BRCA and higher tumor expression in LUAD. The BRCA box plot shows higher RPL12P23 RNA expression in normal versus tumor tissue (log2 FC = −0.018, t-test p = .025).
This table shows molecular features associated with RPL12P23 in patient tissues and cancer cell lines. In patient samples, RPL12P23 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
